A Novel Manufacturing Process for Therapeutic T cells Including CAR T cells
An improved process to manufacture CAR T cells or other therapeutic T cells that is faster and less labor-intensive compared to existing processes
The current process for producing genetically modified cells for use in therapies, including CAR T cell therapy, is costly, time consuming and labor intensive. Cells are grown in cell culture bags, constantly monitored and fed under sterile conditions. The cell product is grown for about 14 to 21 days or longer with close monitoring, which also limits the number of simultaneous products that can be produced in the manufacturing facility.
Dr. Michael Jensen and Dr. Joshua Gustafson have invented a novel process for manufacturing lentivirus transduced T cells that is faster than the current standard by at least seven days. The process involves minimal physical manipulation and uses a novel media composition that allows for co-culturing CD4 and CD8 T cells. All steps of the process can be performed in a closed system, which allows for preparation of CAR T cells for multiple patients within the same space. This process improves workflow and facility design, enables high-efficiency manufacturing and better usage of space and staff.
- GMP manufacturing of primary immune cell therapy products
- Entire process can be performed in a completely closed system
- Faster compared to existing processes
- Amenable to high-throughput manufacturing in minimal square footage
- Co-culture of CD4 and CD8 T cells in a single vessel
The global T-cell therapy market was worth USD $2.4 billion in 2018 and is expected to grow at a CAGR of 15.4% from 2018 to 2027. The value of CAR T-cell therapy market is expected to reach USD $2.9 billion by 2023, growing at a CAGR of 44.1% from 2018 to 2023.
National Phase applications based on PCT/US2019/016497
Michael Jensen, MD
Joshua Gustafson, PhD
To learn more about this technology, please email Kamya Rajaram.